Doug Nixon, MD, PhD

Displaying 1 - 228 of 228

  1. de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF, Michaud HA. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. Retrovirology. 2017 Aug 22; 14(1):41. View on Pubmed
  2. Gurfein BT, Hasdemir B, Milush JM, Touma C, Palme R, Nixon DF, Darcel N, Hecht FM, Bhargava A. Enriched environment and stress exposure influence splenic B lymphocyte composition. PLoS One. 2017; 12(7):e0180771. View on Pubmed
  3. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. Correction: p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2017; 12(4):e0176509. View on Pubmed
  4. Paquin-Proulx D, Greenspun BC, Costa EA, Segurado AC, Kallas EG, Nixon DF, Leal FE. MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: Potential clinical implications. PLoS One. 2017; 12(4):e0175345. View on Pubmed
  5. Wu JJ, Gilbert KE, Batech M, Manalo IF, Towner WJ, Raposo RA, Nixon DF, Liao W. Examining HIV Viral Load in a Matched Cohort of HIV Positive Individuals With and Without Psoriasis. J Drugs Dermatol. 2017 Apr 01; 16(4):372-377. View on Pubmed
  6. Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Nixon DF, Vercauteren J, Brassat D, Liblau R, Vandamme AM, Galvão-Castro B, Van Weyenbergh J. A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. Front Immunol. 2017; 8:97. View on Pubmed
  7. Geddes VEV, José DP, Leal FE, Nixon DF, Tanuri A, Aguiar RS. HTLV-1 Tax activates HIV-1 transcription in latency models. Virology. 2017 Apr; 504:45-51. View on Pubmed
  8. Raposo RA, de Mulder Rougvie M, Paquin-Proulx D, Brailey PM, Cabido VD, Zdinak PM, Thomas AS, Huang SH, Beckerle GA, Jones RB, Nixon DF. IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight. 2017 Jan 12; 2(1):e85811. View on Pubmed
  9. Ornelas AM, Pezzuto P, Silveira PP, Melo FO, Ferreira TA, Oliveira-Szejnfeld PS, Leal JI, Amorim MM, Hamilton S, Rawlinson WD, Cardoso CC, Nixon DF, Tanuri A, Melo AS, Aguiar RS. Immune activation in amniotic fluid from Zika virus-associated microcephaly. Ann Neurol. 2017 Jan; 81(1):152-156. View on Pubmed
  10. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Passero LFD, Hunt PW, Deeks SG, Nixon DF, SenGupta D. p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS One. 2016; 11(11):e0166759. View on Pubmed
  11. Nititham J, Gupta R, Zeng X, Hartogensis W, Nixon DF, Deeks SG, Hecht FM, Liao W. Psoriasis risk SNPs and their association with HIV-1 control. Hum Immunol. 2017 Feb; 78(2):179-184. View on Pubmed
  12. Paquin-Proulx D, Gibbs A, Bächle SM, Checa A, Introini A, Leeansyah E, Wheelock CE, Nixon DF, Broliden K, Tjernlund A, Moll M, Sandberg JK. Innate Invariant NKT Cell Recognition of HIV-1-Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune Evasion. J Immunol. 2016 Sep 01; 197(5):1843-51. View on Pubmed
  13. Willberg CB, Garrison KE, Jones RB, Meiklejohn DA, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF. Correction: Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes. PLoS One. 2016; 11(7):e0160293. View on Pubmed
  14. Paquin-Proulx D, Barsotti NS, Santos BA, Marinho AK, Kokron CM, Carvalho KI, Barros MT, Kalil J, Nixon DF, Kallas EG. Inversion of the Vd1 to Vd2 ?d T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion. Medicine (Baltimore). 2016 Jul; 95(30):e4304. View on Pubmed
  15. Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF. Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial. J Acquir Immune Defic Syndr. 2016 Jun 01; 72(2):184-8. View on Pubmed
  16. Paquin-Proulx D, Ching C, Vujkovic-Cvijin I, Fadrosh D, Loh L, Huang Y, Somsouk M, Lynch SV, Hunt PW, Nixon DF, SenGupta D. Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection. Mucosal Immunol. 2017 Jan; 10(1):69-78. View on Pubmed
  17. Daubenmier J, Moran PJ, Kristeller J, Acree M, Bacchetti P, Kemeny ME, Dallman M, Lustig RH, Grunfeld C, Nixon DF, Milush JM, Goldman V, Laraia B, Laugero KD, Woodhouse L, Epel ES, Hecht FM. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity (Silver Spring). 2016 Apr; 24(4):794-804. View on Pubmed
  18. Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF. Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis. 2016 Feb 15; 213(4):569-73. View on Pubmed
  19. Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8379-84. View on Pubmed
  20. Almeida RR, Raposo RA, Coirada FC, da Silva JR, de Souza Ferreira LC, Kalil J, Nixon DF, Cunha-Neto E. Modulating APOBEC expression enhances DNA vaccine immunogenicity. Immunol Cell Biol. 2015 Nov; 93(10):868-76. View on Pubmed
  21. Eriksson EM, Liegler T, Keh CE, Karlsson AC, Holditch SJ, Pilcher CD, Loeb L, Nixon DF, Hecht FM. Newly Exerted T Cell Pressures on Mutated Epitopes following Transmission Help Maintain Consensus HIV-1 Sequences. PLoS One. 2014; 10(4):e0120787. View on Pubmed
  22. Raposo RA, Gupta R, Abdel-Mohsen M, Dimon M, Debbaneh M, Jiang W, York VA, Leadabrand KS, Brown G, Malakouti M, Arron S, Kuebler PJ, Wu JJ, Pillai SK, Nixon DF, Liao W. Antiviral gene expression in psoriasis. J Eur Acad Dermatol Venereol. 2015 Oct; 29(10):1951-7. View on Pubmed
  23. Nixon DF, Simon GL, Raposo RA. Test, treat, and cure. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):e9-10. View on Pubmed
  24. Leal FE, Michniowski M, Nixon DF. Human T-lymphotropic virus 1, breastfeeding, and antiretroviral therapy. AIDS Res Hum Retroviruses. 2015 Mar; 31(3):271. View on Pubmed
  25. Ribeiro SP, Milush JM, Cunha-Neto E, Kallas EG, Kalil J, Somsouk M, Hunt PW, Deeks SG, Nixon DF, SenGupta D. The CD8? memory stem T cell (T(SCM)) subset is associated with improved prognosis in chronic HIV-1 infection. J Virol. 2014 Dec; 88(23):13836-44. View on Pubmed
  26. Gupta R, Michaud HA, Zeng X, Debbaneh M, Arron ST, Jones RB, Ormsby CE, Nixon DF, Liao W. Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis. J Transl Med. 2014 Sep 16; 12:256. View on Pubmed
  27. Raposo RA, Abdel-Mohsen M, Deng X, Hecht FM, Pilcher CD, Pillai SK, Nixon DF. Dynamic regulation of host restriction factor expression over the course of HIV-1 infection in vivo. J Virol. 2014 Oct; 88(19):11624-9. View on Pubmed
  28. Michaud HA, SenGupta D, de Mulder M, Deeks SG, Martin JN, Kobie JJ, Sacha JB, Nixon DF. Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells. J Immunol. 2014 Aug 15; 193(4):1544-8. View on Pubmed
  29. Gurfein BT, Davidenko O, Premenko-Lanier M, Milush JM, Acree M, Dallman MF, Touma C, Palme R, York VA, Fromentin G, Darcel N, Nixon DF, Hecht FM. Environmental enrichment alters splenic immune cell composition and enhances secondary influenza vaccine responses in mice. Mol Med. 2014 Apr 22; 20:179-90. View on Pubmed
  30. Sheppard NC, Jones RB, Burwitz BJ, Nimityongskul FA, Newman LP, Buechler MB, Reed JS, Piaskowski SM, Weisgrau KL, Castrovinci PA, Wilson NA, Ostrowski MA, Park B, Nixon DF, Rakasz EG, Sacha JB. Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication. PLoS One. 2014; 9(3):e92012. View on Pubmed
  31. Loh L, Ivarsson MA, Michaëlsson J, Sandberg JK, Nixon DF. Invariant natural killer T cells developing in the human fetus accumulate and mature in the small intestine. Mucosal Immunol. 2014 Sep; 7(5):1233-43. View on Pubmed
  32. Michaud HA, de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology. 2014 Jan 28; 11:10. View on Pubmed
  33. Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014; 9(1):e85613. View on Pubmed
  34. Leeansyah E, Loh L, Nixon DF, Sandberg JK. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nat Commun. 2014; 5:3143. View on Pubmed
  35. Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, Lanier LL, Nixon DF. CD56negCD16? NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology. 2013 Dec 18; 10:158. View on Pubmed
  36. Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem Hel-D, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013 Oct 16; 10:106. View on Pubmed
  37. Jones RB, Song H, Xu Y, Garrison KE, Buzdin AA, Anwar N, Hunter DV, Mujib S, Mihajlovic V, Martin E, Lee E, Kuciak M, Raposo RA, Bozorgzad A, Meiklejohn DA, Ndhlovu LC, Nixon DF, Ostrowski MA. LINE-1 retrotransposable element DNA accumulates in HIV-1-infected cells. J Virol. 2013 Dec; 87(24):13307-20. View on Pubmed
  38. de Mulder M, York VA, Wiznia AA, Michaud HA, Nixon DF, Holguin A, Rosenberg MG. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. HIV Med. 2014 Mar; 15(3):135-43. View on Pubmed
  39. Raposo RA, Abdel-Mohsen M, Bilska M, Montefiori DC, Nixon DF, Pillai SK. Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. J Virol. 2013 Nov; 87(21):11924-9. View on Pubmed
  40. Ivarsson MA, Loh L, Marquardt N, Kekäläinen E, Berglin L, Björkström NK, Westgren M, Nixon DF, Michaëlsson J. Differentiation and functional regulation of human fetal NK cells. J Clin Invest. 2013 Sep; 123(9):3889-901. View on Pubmed
  41. Raposo RA, Abdel-Mohsen M, Holditch SJ, Kuebler PJ, Cheng RG, Eriksson EM, Liao W, Pillai SK, Nixon DF. Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals. J Leukoc Biol. 2013 Nov; 94(5):1051-9. View on Pubmed
  42. Snyder-Cappione JE, Nixon DF, Chi JC, Nguyen ML, Kirby CK, Milush JM, Koth LL. Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. Eur J Immunol. 2013 Aug; 43(8):2194-205. View on Pubmed
  43. Sanabani SS, Pessôa R, Soares de Oliveira AC, Martinez VP, Giret MT, de Menezes Succi RC, Carvalho K, Tomiyama CS, Nixon DF, Sabino EC, Kallas EG. Variability of HIV-1 genomes among children and adolescents from São Paulo, Brazil. PLoS One. 2013; 8(5):e62552. View on Pubmed
  44. Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF. T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques. J Virol. 2013 Jun; 87(11):6073-80. View on Pubmed
  45. Batista MD, Tincati C, Milush JM, Ho EL, Ndhlovu LC, York VA, Kallas EG, Kalil J, Keating SM, Norris PJ, Chang D, Unemori P, Leslie KS, Maurer T, Liao W, Nixon DF. CD57 expression and cytokine production by T cells in lesional and unaffected skin from patients with psoriasis. PLoS One. 2013; 8(2):e52144. View on Pubmed
  46. Leal FE, Ndhlovu LC, Hasenkrug AM, Bruno FR, Carvalho KI, Wynn-Williams H, Neto WK, Sanabani SS, Segurado AC, Nixon DF, Kallas EG. Expansion in CD39? CD4? immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications. PLoS Negl Trop Dis. 2013; 7(2):e2028. View on Pubmed
  47. Jones RB, Leal FE, Hasenkrug AM, Segurado AC, Nixon DF, Ostrowski MA, Kallas EG. Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods. J Negat Results Biomed. 2013 Jan 10; 12:3. View on Pubmed
  48. Perez CL, Milush JM, Buggert M, Eriksson EM, Larsen MV, Liegler T, Hartogensis W, Bacchetti P, Lund O, Hecht FM, Nixon DF, Karlsson AC. Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):602-12. View on Pubmed
  49. Batista MD, Ho EL, Kuebler PJ, Milush JM, Lanier LL, Kallas EG, York VA, Chang D, Liao W, Unemori P, Leslie KS, Maurer T, Nixon DF. Skewed distribution of natural killer cells in psoriasis skin lesions. Exp Dermatol. 2013 Jan; 22(1):64-6. View on Pubmed
  50. Keh CE, Jha AR, Nzarubara B, Lanar DE, Dutta S, Theisen M, Rosenthal PJ, Dorsey G, Nixon DF, Greenhouse B. Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda. PLoS One. 2012; 7(12):e52571. View on Pubmed
  51. Eriksson EM, Keh CE, Deeks SG, Martin JN, Hecht FM, Nixon DF. Differential expression of CD96 surface molecule represents CD8? T cells with dissimilar effector function during HIV-1 infection. PLoS One. 2012; 7(12):e51696. View on Pubmed
  52. Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, Hunter DV, Martin E, John VM, Zhan W, Faruk NF, Gyenes G, Sheppard NC, Priumboom-Brees IM, Goodwin DA, Chen L, Rieger M, Muscat-King S, Loudon PT, Stanley C, Holditch SJ, Wong JC, Clayton K, Duan E, Song H, Xu Y, SenGupta D, Tandon R, Sacha JB, Brockman MA, Benko E, Kovacs C, Nixon DF, Ostrowski MA. HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest. 2012 Dec; 122(12):4473-89. View on Pubmed
  53. Tandon R, Giret MT, Sengupta D, York VA, Wiznia AA, Rosenberg MG, Kallas EG, Ndhlovu LC, Nixon DF. Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children. PLoS One. 2012; 7(9):e45733. View on Pubmed
  54. Ormsby CE, Sengupta D, Tandon R, Deeks SG, Martin JN, Jones RB, Ostrowski MA, Garrison KE, Vázquez-Pérez JA, Reyes-Terán G, Nixon DF. Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection. PLoS One. 2012; 7(8):e41021. View on Pubmed
  55. Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF. Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection. PLoS One. 2012; 7(6):e39311. View on Pubmed
  56. Sacha JB, Kim IJ, Chen L, Ullah JH, Goodwin DA, Simmons HA, Schenkman DI, von Pelchrzim F, Gifford RJ, Nimityongskul FA, Newman LP, Wildeboer S, Lappin PB, Hammond D, Castrovinci P, Piaskowski SM, Reed JS, Beheler KA, Tharmanathan T, Zhang N, Muscat-King S, Rieger M, Fernandes C, Rumpel K, Gardner JP, Gebhard DH, Janies J, Shoieb A, Pierce BG, Trajkovic D, Rakasz E, Rong S, McCluskie M, Christy C, Merson JR, Jones RB, Nixon DF, Ostrowski MA, Loudon PT, Pruimboom-Brees IM, Sheppard NC. Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic. J Immunol. 2012 Aug 01; 189(3):1467-79. View on Pubmed
  57. Sandberg JK, Andersson SK, Bächle SM, Nixon DF, Moll M. HIV-1 Vpu interference with innate cell-mediated immune mechanisms. Curr HIV Res. 2012 Jun; 10(4):327-33. View on Pubmed
  58. Gurfein BT, Stamm AW, Bacchetti P, Dallman MF, Nadkarni NA, Milush JM, Touma C, Palme R, Di Borgo CP, Fromentin G, Lown-Hecht R, Konsman JP, Acree M, Premenko-Lanier M, Darcel N, Hecht FM, Nixon DF. The calm mouse: an animal model of stress reduction. Mol Med. 2012 May 09; 18:606-17. View on Pubmed
  59. Carvalho KI, Bruno FR, Snyder-Cappione JE, Maeda SM, Tomimori J, Xavier MB, Haslett PA, Nixon DF, Kallas EG. Lower numbers of natural killer T cells in HIV-1 and Mycobacterium leprae co-infected patients. Immunology. 2012 May; 136(1):96-102. View on Pubmed
  60. Lai OY, Chen H, Michaud HA, Hayashi G, Kuebler PJ, Hultman GK, Ariza ME, Williams MV, Batista MD, Nixon DF, Foerster J, Bowcock AM, Liao W. Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility. J Invest Dermatol. 2012 Jul; 132(7):1833-40. View on Pubmed
  61. Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012 Apr 19; 119(16):3734-43. View on Pubmed
  62. Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV, Martin MP, Fernandez Vina MA, McVean G, Wabl M, Leslie KS, Maurer T, Martin JN, Deeks SG, Carrington M, Bowcock AM, Nixon DF, Liao W. Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet. 2012 Feb; 8(2):e1002514. View on Pubmed
  63. Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF. Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children. PLoS One. 2012; 7(1):e29154. View on Pubmed
  64. Holditch SJ, Eriksson EM, Tarosso LF, Kuebler PJ, Kallas EG, Nielsen EK, Wiznia AA, Rosenberg MG, Nixon DF. Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol. 2011; 2:94. View on Pubmed
  65. de Vos G, Milush JM, Aaron J, Pichardo Y, York VA, Nazari R, Rosenstreich D, Nixon DF, Wiznia A. Peripheral CD8+ T-cell levels are decreased in atopic wheezing children aged less than 4 years. J Investig Allergol Clin Immunol. 2012; 22(6):442-4. View on Pubmed
  66. Jones RB, John VM, Hunter DV, Martin E, Mujib S, Mihajlovic V, Burgers PC, Luider TM, Gyenes G, Sheppard NC, Sengupta D, Tandon R, Yue FY, Benko E, Kovacs C, Nixon DF, Ostrowski MA. Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening. Clin Vaccine Immunol. 2012 Feb; 19(2):288-92. View on Pubmed
  67. Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, Keh CE, Norris PJ, Keating SM, Deeks SG, Hunt PW, Martin JN, Rosenberg MG, Hecht FM, Nixon DF. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood. 2012 Jan 19; 119(3):745-55. View on Pubmed
  68. Tandon R, SenGupta D, Ndhlovu LC, Vieira RG, Jones RB, York VA, Vieira VA, Sharp ER, Wiznia AA, Ostrowski MA, Rosenberg MG, Nixon DF. Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects. J Virol. 2011 Nov; 85(21):11526-31. View on Pubmed
  69. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL. Expansion of a unique CD57?NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011 Sep 06; 108(36):14725-32. View on Pubmed
  70. Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF. Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents. PLoS One. 2011; 6(7):e21135. View on Pubmed
  71. Jha AR, Nixon DF, Rosenberg MG, Martin JN, Deeks SG, Hudson RR, Garrison KE, Pillai SK. Human endogenous retrovirus K106 (HERV-K106) was infectious after the emergence of anatomically modern humans. PLoS One. 2011; 6(5):e20234. View on Pubmed
  72. SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE, Loh L, Jones RB, Garrison KE, Martin JN, York VA, Spotts G, Reyes-Terán G, Ostrowski MA, Hecht FM, Deeks SG, Nixon DF. Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol. 2011 Jul; 85(14):6977-85. View on Pubmed
  73. Ndhlovu LC, Leal FE, Hasenkrug AM, Jha AR, Carvalho KI, Eccles-James IG, Bruno FR, Vieira RG, York VA, Chew GM, Jones RB, Tanaka Y, Neto WK, Sanabani SS, Ostrowski MA, Segurado AC, Nixon DF, Kallas EG. HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications. PLoS Negl Trop Dis. 2011 Apr 26; 5(4):e1030. View on Pubmed
  74. Kuylenstierna C, Snyder-Cappione JE, Loo CP, Long BR, Gonzalez VD, Michaëlsson J, Moll M, Spotts G, Hecht FM, Nixon DF, Sandberg JK. NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection. Scand J Immunol. 2011 Feb; 73(2):141-6. View on Pubmed
  75. Snyder-Cappione JE, Tincati C, Eccles-James IG, Cappione AJ, Ndhlovu LC, Koth LL, Nixon DF. A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-a and MIP1-ß, a lack of IL-17, and a Th1-bias in males. PLoS One. 2010 Nov 03; 5(11):e15412. View on Pubmed
  76. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis. 2010 Oct 15; 202 Suppl 2:S302-8. View on Pubmed
  77. Carvalho KI, Melo KM, Bruno FR, Snyder-Cappione JE, Nixon DF, Costa-Carvalho BT, Kallas EG. Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID). PLoS One. 2010 Sep 09; 5(9). View on Pubmed
  78. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010 Nov 11; 116(19):3865-74. View on Pubmed
  79. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, Jha AR, Eccles-James I, Tincati C, Levy JA, Nixon DF, Hecht FM, Barbour JD. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol. 2010 Sep; 30(5):681-92. View on Pubmed
  80. Willberg CB, Garrison KE, Jones RB, Meiklejohn DJ, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF. Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One. 2010 Apr 21; 5(4):e10249. View on Pubmed
  81. Ndhlovu LC, Leal FE, Eccles-James IG, Jha AR, Lanteri M, Norris PJ, Barbour JD, Wachter DJ, Andersson J, Taskén K, Torheim EA, Aandahl EM, Kallas EG, Nixon DF. A novel human CD4+ T-cell inducer subset with potent immunostimulatory properties. Eur J Immunol. 2010 Jan; 40(1):134-41. View on Pubmed
  82. Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, Hecht FM. Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):36-46. View on Pubmed
  83. Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, Owen RE, Heitman JW, Custer B, Hirschkorn DF, Tobler LH, Kiely N, Prince HE, Ndhlovu LC, Nixon DF, Kamel HT, Kelvin DJ, Busch MP, Rudensky AY, Diamond MS, Norris PJ. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest. 2009 Nov; 119(11):3266-77. View on Pubmed
  84. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, Ndhlovu LC, Lanier LL, Michaëlsson J, Nixon DF. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood. 2009 Nov 26; 114(23):4823-31. View on Pubmed
  85. Snyder-Cappione JE, Loo CP, Carvalho KI, Kuylenstierna C, Deeks SG, Hecht FM, Rosenberg MG, Sandberg JK, Kallas EG, Nixon DF. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS. 2009 Sep 24; 23(15):1965-70. View on Pubmed
  86. Ndhlovu LC, Snyder-Cappione JE, Carvalho KI, Leal FE, Loo CP, Bruno FR, Jha AR, Devita D, Hasenkrug AM, Barbosa HM, Segurado AC, Nixon DF, Murphy EL, Kallas EG. Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clin Exp Immunol. 2009 Dec; 158(3):294-9. View on Pubmed
  87. Jha AR, Pillai SK, York VA, Sharp ER, Storm EC, Wachter DJ, Martin JN, Deeks SG, Rosenberg MG, Nixon DF, Garrison KE. Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens. Mol Biol Evol. 2009 Nov; 26(11):2617-26. View on Pubmed
  88. Long BR, Erickson AE, Chapman JM, Barbour JD, Vu BA, Ho EL, Lanier LL, Sauer MM, Carvalho KI, Nixon DF, Kallas EG. Increased number and function of natural killer cells in human immunodeficiency virus 1-positive subjects co-infected with herpes simplex virus 2. Immunology. 2010 Feb; 129(2):186-96. View on Pubmed
  89. Melo KM, Carvalho KI, Bruno FR, Ndhlovu LC, Ballan WM, Nixon DF, Kallas EG, Costa-Carvalho BT. A decreased frequency of regulatory T cells in patients with common variable immunodeficiency. PLoS One. 2009 Jul 29; 4(7):e6269. View on Pubmed
  90. Garrison KE, Champiat S, York VA, Agrawal AT, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol. 2009 Sep; 16(9):1369-71. View on Pubmed
  91. Loo CP, Long BR, Hecht FM, Nixon DF, Michaëlsson J. HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens. AIDS Res Hum Retroviruses. 2009 Jun; 25(6):603-5. View on Pubmed
  92. Torheim EA, Ndhlovu LC, Pettersen FO, Larsen TL, Jha AR, Torgersen KM, Kvale D, Nixon DF, Taskén K, Aandahl EM. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol. 2009 May; 39(5):1280-7. View on Pubmed
  93. Cheng RG, Nixon DF. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis. 2009 Feb; 9(2):74; author reply 74-5. View on Pubmed
  94. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, Lee TH, Nixon DF, McCune JM. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science. 2008 Dec 05; 322(5907):1562-5. View on Pubmed
  95. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008 Nov 24; 205(12):2763-79. View on Pubmed
  96. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, Hecht FM, Grant RM, Nixon DF. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog. 2008 Oct; 4(10):e1000185. View on Pubmed
  97. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, Grant RM, Nixon DF. Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol. 2008 Nov; 15(11):1745-8. View on Pubmed
  98. Michaëlsson J, Barbosa HM, Jordan KA, Chapman JM, Brunialti MK, Neto WK, Nukui Y, Sabino EC, Chieia MA, Oliveira AS, Nixon DF, Kallas EG. The frequency of CD127low expressing CD4+CD25high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis. BMC Immunol. 2008 Jul 29; 9:41. View on Pubmed
  99. Ndhlovu LC, Chapman JM, Jha AR, Snyder-Cappione JE, Pagán M, Leal FE, Boland BS, Norris PJ, Rosenberg MG, Nixon DF. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS. 2008 May 11; 22(8):990-2. View on Pubmed
  100. McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Li J, Beckett L, Shacklett BL, Evans TG, Asmuth DM. Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms. Cytometry A. 2008 May; 73(5):411-20. View on Pubmed
  101. McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Oxford C, Evans TG, Asmuth DM. Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry A. 2008 May; 73(5):400-10. View on Pubmed
  102. Pérez CL, Larsen MV, Gustafsson R, Norström MM, Atlas A, Nixon DF, Nielsen M, Lund O, Karlsson AC. Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol. 2008 Apr 01; 180(7):5092-100. View on Pubmed
  103. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, Barbour JD. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol. 2008 May; 82(10):4785-92. View on Pubmed
  104. Jones RB, Garrison KE, Wong JC, Duan EH, Nixon DF, Ostrowski MA. Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition. PLoS One. 2008 Feb 06; 3(2):e1547. View on Pubmed
  105. Lee AW, Sharp ER, O'Mahony A, Rosenberg MG, Israelski DM, Nolan GP, Nixon DF. Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J Virol. 2008 Apr; 82(7):3702-12. View on Pubmed
  106. Michaëlsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, Nixon DF. Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis. 2008 Jan 01; 197(1):117-25. View on Pubmed
  107. Long BR, Michaelsson J, Loo CP, Ballan WM, Vu BA, Hecht FM, Lanier LL, Chapman JM, Nixon DF. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol. 2008 Jan; 15(1):120-30. View on Pubmed
  108. Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM. FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol. 2008 Feb; 83(2):254-62. View on Pubmed
  109. Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM, Erickson AL, Agrawal A, Spotts G, Hecht FM, Rakoff-Nahoum S, Lenz J, Ostrowski MA, Nixon DF. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog. 2007 Nov; 3(11):e165. View on Pubmed
  110. Barbour JD, Sauer MM, Sharp ER, Garrison KE, Long BR, Tomiyama H, Bassichetto KC, Oliveira SM, Abbate MC, Nixon DF, Kallas EG. HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS One. 2007 Oct 24; 2(10):e1080. View on Pubmed
  111. Ballan WM, Vu BA, Long BR, Loo CP, Michaëlsson J, Barbour JD, Lanier LL, Wiznia AA, Abadi J, Fennelly GJ, Rosenberg MG, Nixon DF. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol. 2007 Sep 01; 179(5):3362-70. View on Pubmed
  112. Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol. 2007 Oct; 81(20):11543-8. View on Pubmed
  113. Willberg CB, Pillai SK, Sharp ER, Rosenberg MG, Agudelo JD, Barbour JD, Nixon DF. Rational peptide selection to detect human immunodeficiency virus type 1-specific T-cell responses under resource-limited conditions. Clin Vaccine Immunol. 2007 Jun; 14(6):785-8. View on Pubmed
  114. Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, Klenerman P, Nixon DF, Michaëlsson J. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol. 2007 Jun; 81(11):5759-65. View on Pubmed
  115. Snyder-Cappione JE, Nixon DF, Loo CP, Chapman JM, Meiklejohn DA, Melo FF, Costa PR, Sandberg JK, Rodrigues DS, Kallas EG. Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J Infect Dis. 2007 May 01; 195(9):1361-4. View on Pubmed
  116. Karlsson AC, Iversen AK, Chapman JM, de Oliviera T, Spotts G, McMichael AJ, Davenport MP, Hecht FM, Nixon DF. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One. 2007 Feb 21; 2(2):e225. View on Pubmed
  117. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol. 2007 Jan 15; 178(2):647-51. View on Pubmed
  118. Willberg CB, Nixon DF. Treatment interruption in chronic HIV-1 infection: does it deliver? Curr Opin HIV AIDS. 2007 Jan; 2(1):26-30. View on Pubmed
  119. Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology. 2006 Dec 21; 3:97. View on Pubmed
  120. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, Diaz RS, Santos AM, Succi RC, Abadi J, Rosenberg MG, de Moraes-Pinto MI, Kallas EG. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One. 2006 Dec 20; 1:e102. View on Pubmed
  121. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5. View on Pubmed
  122. Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN, McCune JM, Nixon DF, Maecker HT. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006 Jul 21; 3:18. View on Pubmed
  123. Michaëlsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses in the developing human fetus. J Immunol. 2006 May 15; 176(10):5741-8. View on Pubmed
  124. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, Bentsen C, Ramstead CA, Nixon DF, Levy JA, Hecht FM. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis. 2006 Mar 01; 42(5):700-8. View on Pubmed
  125. Jordan KA, Furlan SN, Gonzalez VD, Karlsson AC, Quigley MF, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. CD8 T cell effector maturation in HIV-1-infected children. Virology. 2006 Mar 30; 347(1):117-26. View on Pubmed
  126. Papasavvas E, Kostman JR, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan KA, Nixon DF, Grant R, Poulin JF, McCune JM, Mounzer K, Montaner LJ. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol. 2006 Jan; 26(1):40-54. View on Pubmed
  127. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses. 2006 Jan; 22(1):52-6. View on Pubmed
  128. Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood. 2006 Apr 15; 107(8):3081-3. View on Pubmed
  129. Metzner KJ, Moretto WJ, Donahoe SM, Jin X, Gettie A, Montefiori DC, Marx PA, Binley JM, Nixon DF, Connor RI. Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. J Gen Virol. 2005 Dec; 86(Pt 12):3375-84. View on Pubmed
  130. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. 2005 Nov; 79(22):14169-78. View on Pubmed
  131. Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, Wiznia AA, Nixon DF, Rosenberg MG. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005 Oct 14; 19(15):1575-85. View on Pubmed
  132. Sharp ER, Barbour JD, Karlsson RK, Jordan KA, Sandberg JK, Wiznia A, Rosenberg MG, Nixon DF. Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1. J Infect Dis. 2005 Nov 15; 192(10):1772-80. View on Pubmed
  133. Nixon DF, Deeks SG, Shacklett BL, Karlsson AC. Multidrug-resistant, dual-tropic HIV-1 and rapid progression. Lancet. 2005 Jun 4-10; 365(9475):1924-5. View on Pubmed
  134. Nixon DF, Aandahl EM, Michaëlsson J. CD4+CD25+ regulatory T cells in HIV infection. Microbes Infect. 2005 Jun; 7(7-8):1063-5. View on Pubmed
  135. Schweighardt B, Roy AM, Meiklejohn DA, Grace EJ, Moretto WJ, Heymann JJ, Nixon DF. R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. J Virol. 2004 Sep; 78(17):9164-73. View on Pubmed
  136. Aandahl EM, Quigley MF, Moretto WJ, Moll M, Gonzalez VD, Sönnerborg A, Lindbäck S, Hecht FM, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood. 2004 Dec 01; 104(12):3672-8. View on Pubmed
  137. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr. 2004 Jul 01; 36(3):791-9. View on Pubmed
  138. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, Andersson J, Sandberg JK, Nixon DF. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. J Immunol. 2004 Jul 01; 173(1):641-8. View on Pubmed
  139. Shacklett BL, Cox CA, Wilkens DT, Karl Karlsson R, Nilsson A, Nixon DF, Price RW. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis. 2004 Jun 15; 189(12):2202-12. View on Pubmed
  140. Meiklejohn DA, Karlsson RK, Karlsson AC, Chapman JM, Nixon DF, Schweighardt B. ELISPOT cell rescue. J Immunol Methods. 2004 May; 288(1-2):135-47. View on Pubmed
  141. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004 Apr 30; 18(7):981-9. View on Pubmed
  142. Sandberg JK, Stoddart CA, Brilot F, Jordan KA, Nixon DF. Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci U S A. 2004 May 04; 101(18):7058-63. View on Pubmed
  143. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, Montefiori D, Earl P, Moss B, Rose JK. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol. 2004 Apr; 78(8):3930-40. View on Pubmed
  144. Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004 Mar; 78(5):2454-9. View on Pubmed
  145. Karlsson RK, Jennes W, Page-Shafer K, Nixon DF, Shacklett BL. Poorly soluble peptides can mimic authentic ELISPOT responses. J Immunol Methods. 2004 Feb 01; 285(1):89-92. View on Pubmed
  146. Chandwani R, Jordan KA, Shacklett BL, Papasavvas E, Montaner LJ, Rosenberg MG, Nixon DF, Sandberg JK. Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infection. Scand J Immunol. 2004 Jan; 59(1):109-14. View on Pubmed
  147. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):475-81. View on Pubmed
  148. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003 Dec; 283(1-2):141-53. View on Pubmed
  149. Papasavvas E, Sandberg JK, Rutstein R, Moore EC, Mackiewicz A, Thiel B, Pistilli M, June RR, Jordan KA, Gross R, Maino VC, Nixon DF, Montaner LJ. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression. J Infect Dis. 2003 Sep 15; 188(6):873-82. View on Pubmed
  150. Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, Price C, Fuerst M, Matud J, Hultin P, Cox C, Ibarrondo J, Wong JT, Nixon DF, Anton PA, Jamieson BD. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods. 2003 Aug; 279(1-2):17-31. View on Pubmed
  151. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. View on Pubmed
  152. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF. Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol. 2003 May; 77(10):5621-31. View on Pubmed
  153. Sandberg JK, Fast NM, Jordan KA, Furlan SN, Barbour JD, Fennelly G, Dobroszycki J, Spiegel HM, Wiznia A, Rosenberg MG, Nixon DF. HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol. 2003 Apr 15; 170(8):4403-10. View on Pubmed
  154. Aandahl EM, Sandberg JK, Beckerman KP, Taskén K, Moretto WJ, Nixon DF. CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol. 2003 Mar 01; 170(5):2349-55. View on Pubmed
  155. Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur J Immunol. 2003 Mar; 33(3):588-96. View on Pubmed
  156. Nixon DF, Aandahl EM, Sandberg JK. New observations on CD8 cell responses. AIDS. 2003; 17 Suppl 4:S61-5. View on Pubmed
  157. Jennes W, Kestens L, Nixon DF, Shacklett BL. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15--the Amplispot assay. J Immunol Methods. 2002 Dec 01; 270(1):99-108. View on Pubmed
  158. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. View on Pubmed
  159. Shacklett BL, Ling B, Veazey RS, Luckay A, Moretto WJ, Wilkens DT, Hu J, Israel ZR, Nixon DF, Marx PA. Boosting of SIV-specific T cell responses in rhesus macaques that resist repeated intravaginal challenge with SIVmac251. AIDS Res Hum Retroviruses. 2002 Sep 20; 18(14):1081-8. View on Pubmed
  160. Keir ME, Rosenberg MG, Sandberg JK, Jordan KA, Wiznia A, Nixon DF, Stoddart CA, McCune JM. Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus. J Immunol. 2002 Sep 01; 169(5):2788-96. View on Pubmed
  161. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant RM, Bhardwaj N, Rosenberg MG, Nixon DF. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002 Aug; 76(15):7528-34. View on Pubmed
  162. Shacklett BL, Means RE, Larsson M, Wilkens DT, Beadle TJ, Merritt MJ, Bhardwaj N, Palumbo PE, Skurnick JH, Louria DB, Nixon DF. Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. AIDS Res Hum Retroviruses. 2002 Jul 20; 18(11):805-15. View on Pubmed
  163. Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K, Nixon DF. Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol. 2002 Jul 15; 169(2):802-8. View on Pubmed
  164. Klenerman P, Tolfvenstam T, Price DA, Nixon DF, Broliden K, Oxenius A. T lymphocyte responses against human parvovirus B19: small virus, big response. Pathol Biol (Paris). 2002 Jun; 50(5):317-25. View on Pubmed
  165. Larsson M, Wilkens DT, Fonteneau JF, Beadle TJ, Merritt MJ, Kost RG, Haslett PA, Cu-Uvin S, Bhardwaj N, Nixon DF, Shacklett BL. Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS. 2002 Jan 25; 16(2):171-80. View on Pubmed
  166. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis. 2002 Feb 15; 185(4):428-38. View on Pubmed
  167. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002 Jan; 76(1):411-5. View on Pubmed
  168. Hioe CE, Tuen M, Chien PC, Jones G, Ratto-Kim S, Norris PJ, Moretto WJ, Nixon DF, Gorny MK, Zolla-Pazner S. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol. 2001 Nov; 75(22):10950-7. View on Pubmed
  169. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13288-93. View on Pubmed
  170. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001 Sep 07; 106(5):539-49. View on Pubmed
  171. Sandberg JK, Fast NM, Nixon DF. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol. 2001 Jul 01; 167(1):181-7. View on Pubmed
  172. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001 Jun 15; 15(9):F29-40. View on Pubmed
  173. McDermott AB, Spiegel HM, Irsch J, Ogg GS, Nixon DF. A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells. AIDS. 2001 Apr 13; 15(6):810-2. View on Pubmed
  174. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods. 2001 Mar 01; 249(1-2):99-110. View on Pubmed
  175. Komanduri KV, Donahoe SM, Moretto WJ, Schmidt DK, Gillespie G, Ogg GS, Roederer M, Nixon DF, McCune JM. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology. 2001 Jan 20; 279(2):459-70. View on Pubmed
  176. Tolfvenstam T, Oxenius A, Price DA, Shacklett BL, Spiegel HM, Hedman K, Norbeck O, Levi M, Olsen K, Kantzanou M, Nixon DF, Broliden K, Klenerman P. Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19. J Virol. 2001 Jan; 75(1):540-3. View on Pubmed
  177. Moretto WJ, Drohan LA, Nixon DF. Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. AIDS. 2000 Nov 10; 14(16):2625-7. View on Pubmed
  178. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 2000 Oct 20; 14(15):2313-22. View on Pubmed
  179. Shacklett BL, Cu-Uvin S, Beadle TJ, Pace CA, Fast NM, Donahue SM, Caliendo AM, Flanigan TP, Carpenter CC, Nixon DF. Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. AIDS. 2000 Sep 08; 14(13):1911-5. View on Pubmed
  180. Jin X, Ogg G, Bonhoeffer S, Safrit J, Vesanen M, Bauer D, Chen D, Cao Y, Demoitie MA, Zhang L, Markowitz M, Nixon D, McMichael A, Ho DD. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol Med. 2000 Sep; 6(9):803-9. View on Pubmed
  181. Lechner F, Sullivan J, Spiegel H, Nixon DF, Ferrari B, Davis A, Borkowsky B, Pollack H, Barnes E, Dusheiko G, Klenerman P. Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29; 355(1400):1085-92. View on Pubmed
  182. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75. View on Pubmed
  183. Shacklett BL, Beadle TJ, Pacheco PA, Grendell JH, Haslett PA, King AS, Ogg GS, Basuk PM, Nixon DF. Isolation of cytomegalovirus-specific cytotoxic T-lymphocytes from gut-associated lymphoid tissue (GALT) of HIV type 1-infected subjects. AIDS Res Hum Retroviruses. 2000 Aug 10; 16(12):1157-62. View on Pubmed
  184. Larsson M, Messmer D, Somersan S, Fonteneau JF, Donahoe SM, Lee M, Dunbar PR, Cerundolo V, Julkunen I, Nixon DF, Bhardwaj N. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol. 2000 Aug 01; 165(3):1182-90. View on Pubmed
  185. Donahoe SM, Moretto WJ, Samuel RV, Metzner KJ, Marx PA, Hanke T, Connor RI, Nixon DF. Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus. Virology. 2000 Jul 05; 272(2):347-56. View on Pubmed
  186. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000 Jul 03; 192(1):63-75. View on Pubmed
  187. Spiegel HM, Chandwani R, Sheehy ME, Dobroszycki J, Fennelly G, Wiznia A, Radding J, Rigaud M, Pollack H, Borkowsky W, Rosenberg M, Nixon DF. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. J Infect Dis. 2000 Jul; 182(1):88-95. View on Pubmed
  188. Shacklett BL, Beadle TJ, Pacheco PA, Grendell JH, Haslett PA, King AS, Ogg GS, Basuk PM, Nixon DF. Characterization of HIV-1-specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects. Virology. 2000 May 10; 270(2):317-27. View on Pubmed
  189. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000 Apr; 181(4):1249-63. View on Pubmed
  190. Haslett PA, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, Donahoe SM, Kaplan G. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 2000 Apr; 181(4):1264-72. View on Pubmed
  191. Seth A, Yasutomi Y, Jacoby H, Callery JC, Kaminsky SM, Koff WC, Nixon DF, Letvin NL. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses. 2000 Mar 01; 16(4):337-43. View on Pubmed
  192. Nixon DF, Donahoe SM, Kakimoto WM, Samuel RV, Metzner KJ, Gettie A, Hanke T, Marx PA, Connor RI. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. Virology. 2000 Jan 05; 266(1):203-10. View on Pubmed
  193. Spiegel HM, Ogg GS, DeFalcon E, Sheehy ME, Monard S, Haslett PA, Gillespie G, Donahoe SM, Pollack H, Borkowsky W, McMichael AJ, Nixon DF. Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells. J Virol. 2000 Jan; 74(2):1018-22. View on Pubmed
  194. Jin X, Roberts CG, Nixon DF, Safrit JT, Zhang LQ, Huang YX, Bhardwaj N, Jesdale B, DeGroot AS, Koup RA. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Res Hum Retroviruses. 2000 Jan 01; 16(1):67-76. View on Pubmed
  195. Jin X, Demoitie MA, Donahoe SM, Ogg GS, Bonhoeffer S, Kakimoto WM, Gillespie G, Moss PA, Dyer W, Kurilla MG, Riddell SR, Downie J, Sullivan JS, McMichael AJ, Workman C, Nixon DF. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J Infect Dis. 2000 Jan; 181(1):165-75. View on Pubmed
  196. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep; 104(6):R13-8. View on Pubmed
  197. Spiegel HM, DeFalcon E, Ogg GS, Larsson M, Beadle TJ, Tao P, McMichael AJ, Bhardwaj N, O'Callaghan C, Cox WI, Krasinski K, Pollack H, Borkowsky W, Nixon DF. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis. 1999 Aug; 180(2):359-68. View on Pubmed
  198. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999 Jul; 104(2):173-80. View on Pubmed
  199. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI, Steinman RM, Nixon D, Bhardwaj N. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS. 1999 May 07; 13(7):767-77. View on Pubmed
  200. Nixon DF, Douek D, Kuebler PJ, Jin X, Vesanen M, Bonhoeffer S, Cao Y, Koup RA, Ho DD, Markowitz M. Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol Lett. 1999 Mar; 66(1-3):219-28. View on Pubmed
  201. Kakimoto WM, Gettie A, Smith S, Donahoe SM, Jin X, Marx P, Connor R, Nixon DF. Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors. Immunol Lett. 1999 Mar; 66(1-3):135-40. View on Pubmed
  202. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Jin X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD, J X. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999 Mar; 179(3):527-37. View on Pubmed
  203. Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon DF, Sullivan JS. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol. 1999 Jan; 73(1):436-43. View on Pubmed
  204. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, Nixon DF. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999 Jan; 73(1):797-800. View on Pubmed
  205. Jin X, Roberts CG, Nixon DF, Cao Y, Ho DD, Walker BD, Muldoon M, Korber BT, Koup RA. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators. J Infect Dis. 1998 Nov; 178(5):1317-26. View on Pubmed
  206. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998 Mar 27; 279(5359):2103-6. View on Pubmed
  207. Singh M, Hioe C, Qiu H, Li XM, Wang CY, Koff W, Zamb T, Nixon DF. CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedure. Vaccine. 1997 Nov; 15(16):1773-8. View on Pubmed
  208. Kuebler PJ, Nixon DF. Cytotoxic T cell induction with ratchet peptide libraries. Vaccine. 1996 Dec; 14(17-18):1664-70. View on Pubmed
  209. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine. 1996 Nov; 14(16):1523-30. View on Pubmed
  210. Allsopp CE, Plebanski M, Gilbert S, Sinden RE, Harris S, Frankel G, Dougan G, Hioe C, Nixon D, Paoletti E, Layton G, Hill AV. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol. 1996 Aug; 26(8):1951-9. View on Pubmed
  211. Hioe CE, Qiu H, Chend PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O'Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, Nixon DF. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine. 1996 Apr; 14(5):412-8. View on Pubmed
  212. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, McMichael A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 1993 Apr 03; 341(8849):860-1. View on Pubmed
  213. Sutton J, Rowland-Jones S, Rosenberg W, Nixon D, Gotch F, Gao XM, Murray N, Spoonas A, Driscoll P, Smith M. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol. 1993 Feb; 23(2):447-53. View on Pubmed
  214. Gotch F, Nixon D, Gallimore A, McAdam S, McMichael A. Cytotoxic T lymphocyte epitopes shared between HIV-1, HIV-2, and SIV. J Med Primatol. 1993 Feb-May; 22(2-3):119-23. View on Pubmed
  215. Nixon DF, Broliden K, Ogg G, Broliden PA. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology. 1992 Aug; 76(4):515-34. View on Pubmed
  216. Rowland-Jones SL, Phillips RE, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR. Human immunodeficiency virus variants that escape cytotoxic T-cell recognition. AIDS Res Hum Retroviruses. 1992 Aug; 8(8):1353-4. View on Pubmed
  217. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991 Dec 12; 354(6353):453-9. View on Pubmed
  218. Nixon D. Vaccines for HIV infected pregnant women? BMJ. 1991 Oct 26; 303(6809):1061. View on Pubmed
  219. Nixon DF, McMichael AJ. Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS. 1991 Sep; 5(9):1049-59. View on Pubmed
  220. Nixon DF, Huet S, Rothbard J, Kieny MP, Delchambre M, Thiriart C, Rizza CR, Gotch FM, McMichael AJ. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS. 1990 Sep; 4(9):841-5. View on Pubmed
  221. Gotch FM, Nixon DF, Alp N, McMichael AJ, Borysiewicz LK. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol. 1990; 2(8):707-12. View on Pubmed
  222. Huet S, Nixon DF, Rothbard JB, Townsend A, Ellis SA, McMichael AJ. Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27. Int Immunol. 1990; 2(4):311-6. View on Pubmed
  223. Mills KH, Nixon DF, McMichael AJ. T-cell strategies in AIDS vaccines: MHC-restricted T-cell responses to HIV proteins. AIDS. 1989; 3 Suppl 1:S101-10. View on Pubmed
  224. Nixon DF, McMichael AJ. HIV-gag-specific cytotoxic T lymphocytes. Res Immunol. 1989 Jan; 140(1):107-10; discussion 121. View on Pubmed
  225. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988 Dec 01; 336(6198):484-7. View on Pubmed
  226. McManus C, Newhouse H, Seitz S, Nixon D, Poppendiek H, Heymsfield S. Human gradient-layer calorimeter: development of an accurate and practical instrument for clinical studies. JPEN J Parenter Enteral Nutr. 1984 May-Jun; 8(3):317-20. View on Pubmed
  227. Nixon DF, Ting JP, Frelinger JA. Ia antigens on non-lymphoid tissues their origins and functions. Immunol Today. 1982 Dec; 3(12):339-42. View on Pubmed
  228. Waterfield JD, Nixon DF, Mair MG. Lymphocyte-mediated cytotoxicity against allogeneic tumour cells. IV. Fine specificity mapping and characterization of concanavalin A-activated cytotoxic effector lymphocytes. Immunology. 1981 Dec; 44(4):685-93. View on Pubmed